Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients

Jan 29, 2024

Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024

Jan 23, 2024

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients

Jan 17, 2024

Acurx to present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024

Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure

Dec 11, 2023

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update

Nov 14, 2023

Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection

Nov 2, 2023

Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update

Oct 25, 2023

Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences

Oct 19, 2023

Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection

Oct 2, 2023